Abstract

Exome sequencing of primary tumors identifies complex somatic mutation patterns. Assignment of relevance of individual somatic mutations is difficult and poses the next challenge for interpretation of next generation sequencing data. Here we present an approach how exome sequencing in combination with SNP microarray data may identify targets of chromosomal aberrations in myeloid malignancies. The rationale of this approach is that hotspots of chromosomal aberrations might also harbor point mutations in the target genes of deletions, gains or uniparental disomies (UPDs). Chromosome 11 is a frequent target of lesions in myeloid malignancies. Therefore, we studied chromosome 11 in a total of 813 samples from 773 individual patients with different myeloid malignancies by SNP microarrays and complemented the data with exome sequencing in selected cases exhibiting chromosome 11 defects. We found gains, losses and UPDs of chromosome 11 in 52 of the 813 samples (6.4%). Chromosome 11q UPDs frequently associated with mutations of CBL. In one patient the 11qUPD amplified somatic mutations in both CBL and the DNA repair gene DDB1. A duplication within MLL exon 3 was detected in another patient with 11qUPD. We identified several common deleted regions (CDR) on chromosome 11. One of the CDRs associated with de novo acute myeloid leukemia (P=0.013). One patient with a deletion at the LMO2 locus harbored an additional point mutation on the other allele indicating that LMO2 might be a tumor suppressor frequently targeted by 11p deletions. Our chromosome-centered analysis indicates that chromosome 11 contains a number of tumor suppressor genes and that the role of this chromosome in myeloid malignancies is more complex than previously recognized.

Highlights

  • Hematological malignancies are broadly categorized into myeloid and lymphoid malignancies, depending on the hematopoietic lineage involved

  • This study focused on myeloid malignancies, in particular the disease entities acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS) as well as the three classical myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF)

  • Concluding remarks and perspectives In this study we applied a chromosome centered genetic analysis of myeloid malignancies. The rationale of this approach is that those chromosomes that exhibit frequent chromosomal defects might harbor point mutations in the target genes of deletions, gains or uniparental disomies (UPDs)

Read more

Summary

Introduction

Hematological malignancies are broadly categorized into myeloid and lymphoid malignancies, depending on the hematopoietic lineage involved. In 1991 the gene that was affected by these translocations on chromosome 11 was identified to be MLL (myeloid/lymphoid or mixed-lineage leukemia) [3]. Since a variety of translocations involving MLL and more than 60 fusion gene partners have been identified They are found both, in ALL and AML with a high prevalence in infants [5]. Classical karyotyping has revealed chromosomal deletions as common genetic changes in chronic lymphoid leukemia (CLL), AML, MDS and other hematological malignancies. Alongside others, reported such studies in the myeloproliferative neoplasms (MPN) [11-14] All of these studies observed frequent aberrations on chromosome 11 including gains, losses and UPDs. UPDs were shown to somatically amplify mutant alleles of genes on various chromosomal arms such as 9p (JAK2), 1p (MPL) or 4q (TET2) [15-23]. On the short arm of chromosome 11, mutant alleles of WT1 were associated with UPDs in AML [24], while CBL mutations were associated with UPDs on chromosome

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.